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Abstract
Background: This study investigated prognosis among patients under prolonged mechanical ventilation (PMV)
through exploring the following issues: (1) post-PMV survival rates, (2) factors associated with survival after PMV,
and (3) the number of days alive free of hospital stays requiring mechanical ventilation (MV) care after PMV.
Methods: This is a retrospective cohort study based on secondary analysis of prospectively collected data in the
national health insurance system and governmental data on death registry in Taiwan. It used data for a nationally
representative sample of 25,482 patients becoming under PMV (> = 21 days) during 1998-2003. We calculated
survival rates for the 4 years after PMV, and adopted logistic regression to construct prediction models for
3-month, 6-month, 1-year, and 2-year survival, with data of 1998-2002 for model estimation and the 2003 data for
examination of model performance. We estimated the number of days alive free of hospital stays requiring MV
care in the immediate 4-year period after PMV, and contrasted patients who had low survival probability with all
PMV patients.
Results: Among these patients, the 3-month survival rate was 51.4%, and the 1-year survival rate was 31.9%. Common
health conditions with significant associations with poor survival included neoplasm, acute and unspecific renal failure,
chronic renal failure, non-alcoholic liver disease, shock and septicaemia (odd ratio < 0.7, p < 0.05). During a 4-year
follow-up period for patients of year 2003, the mean number of days free of hospital stays requiring MV was 66.0 in
those with a predicted 6-month survival rate < 10%, and 111.3 in those with a predicted 2-year survival rate < 10%. In
contrast, the mean number of days was 256.9 in the whole sample of patients in 2003.
Conclusions: Neoplasm, acute and unspecific renal failure, shock, chronic renal failure, septicemia, and non-alcoholic
liver disease are significantly associated with lower survival among PMV patients. Patients with anticipated death in a
near future tend to spend most of the rest of their life staying in hospital using MV services. This calls for further
research into assessing PMV care need among patients at different prognosis stages of diseases listed above.
Background
The healthcare arrangements for patients with prolonged
mechanical ventilation (PMV), which is usually defined
as mechanical ventilation (MV) for at least 6 hours per
day for a period of 21 days or more [1], have been an
issue in many countries with advanced medical technol-
ogy. The United States began establishing respiratory
intensive care units in the 1960s [2], while some
European countries introduced facilities specifically for
respiratory care in the 1980s [3].
The healthcare arrangements for such patients have
also been a pressing issue in Taiwan, where a single-
payer national health insurance (NHI) system started in
1995 and has been praised for its reasonable premiums
and co-payments, and relatively short wait times for care
[4,5]. The NHI provided care to all ventilator-dependent
patients in intensive care units (ICUs) initially. Within
three years, however, this care pattern led to a severe
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National Health Insurance (BNHI) introduced “respira-
tory care centres” and “respiratory care wards” in hospi-
tals to provide MV services to PMV patients 17 years of
age or older in non-ICU settings.
As this program greatly increased the availability of
PMV services, the number of PMV patients increased
rapidly after launch of the program. The BNHI reported
that the total number of patients receiving PMV in each
of 2004 and 2005 reached 30,000 (0.13% of the Taiwan
population), and the total annual expenses approached
27 billion New Taiwan dollars (NT$), which was around
6% of the total annual NHI budget. One BNHI report
also reveals that the per-capita annual NHI expenses for
patients receiving PMV in 2009 were 33 times that for all
enrolees, and equal to 56 times the per-capita annual
premium (NT$13,188 in 2009).
Controversial issues have emerged regarding the cost-
effectiveness of extensive use of MV services, as well as
distributive justice in healthcare allocation, because expen-
ditures on this program crowded out resources for other
healthcare in NHI. Another problem following the imple-
mentation of this program was that more physicians have
to confront dilemmas when they have to respond to the
preference of PMV patients or their families for withdraw-
ing life-sustaining treatment after a period of PMV, as
there have been much more PMV patients. It calls for
more research on prognosis among PMV patients, because
participants involved in decisions concerning terminal
withdrawal of MV (including patients’ families and physi-
cians, and members in ethics committees for reviewing
requests to withdraw PMV services) certainly need more
reference materials in the process of decision-making to
help them make better-informed decisions.
This study is an effort to generate helpful reference
information in this regard through using a large national
representative database to explore the following issues: (1)
survival rates after a PMV incidence, (2) factors associated
with survival after PMV, and (3) the number of days alive
free of hospital stays requiring MV care after PMV.
Methods
Study design
This is a retrospective cohort study based on secondary
analysis of prospectively collected data in the NHI system
and governmental data on death registry. It is part of a
research project on PMV care. The National Health
Research Institutes (NHRI), the BNHI, and the Depart-
ment of Health (DOH) approved the research project, and
granted our request to construct a database linking NHI
data and death-certificate data for patients receiving PMV
care in the NHI. All individual identification numbers
were scrambled by the BNHI for privacy protection.
Setting
The study setting was in the NHI system. The NHI cov-
ers and protects almost all Taiwanese, and provides med-
ical services in almost all outpatient visits and hospital
admissions [7]. The NHI care program for PMV patients
17 years of age or older covers invasive ventilators, nega-
tive pressure ventilators, and positive pressure ventilators,
under the condition that at least some use of an invasive
ventilator or a negative pressure ventilator should be
made prior to the first day of using a positive pressure
ventilator [8]. Thus, PMV patients in the NHI only
include those under MV care. Patients with a tracheost-
o m yt u b ei ns i t un o tc o n n e c t e dt oav e n t i l a t o ra r en o t
regarded as ventilator-dependent in the NHI.
While the BNHI defines PMV as ventilation care use for
at least 21 consecutive days, a patient might have ventila-
tion care use for fewer than 21 days at the time of entering
the non-ICU care program for PMV in NHI, because the
BNHI includes periods of discontinuation of MV care that
had a length equal to or shorter than 4 days when aggre-
gating a patient’s time (in days) of use for judging the
patient’s eligibility of entering the program [8]. The BNHI
sets limits on the lengths of stays in ICUs (an acute stage,
< 21 days) and respiratory care centres (a subacute stage
for weaning training, up to 42 days), but no limit for stays
in respiratory care wards (a chronic stage or long-term
care for those with little chance for weaning). Therefore,
the NHI actually sets no limit on how long a patient may
use MV care. The PMV program also includes homecare
services for patients with a stable condition who are cared
by family members or other caregivers at home. However,
extremely few patients use homecare services, because the
family have to pay much higher own expenses under this
care pattern.
Data sources
Two Taiwan governmental organizations provided origi-
nal data for the study. The BNHI provided NHI data, and
the Ministry of the Interior provided data from the
national mandatory death registry system through the
DOH. The BNHI maintains a comprehensive database of
claims and registration data. The NHI database has
detailed information on health services, procedures and
prescriptions provided in the NHI, and their payments
and times of use. It also includes data on diagnoses for
patients, as well as background information on patients,
physicians and healthcare institutions. The NHI system
codes diagnoses using the International Classification of
Diseases, Ninth Revision (ICD-9). The quality of NHI
data is generally reliable, because the BNHI has been rou-
tinely auditing data submitted by healthcare institutions
to prevent fraud in the NHI [9]. In Taiwan, it is also
widely believed that death-certificate data are highly
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tained household registration system of Taiwan.
The database we acquired contains person-level longitu-
dinal NHI claims and registration data for a national
representative sample of patients who ever used invasive
or non-invasive respiratory care in NHI during 1996-2007.
This cohort included 2,619,534 patients, representing 10%
of all NHI enrolees and 29% of all patients ever using any
kind of respiratory care under NHI in these 12 years. This
number of individuals was the maximal number of enro-
lees the government sets for application of NHI data use
in 2008 (the year of our data application). We also
acquired longitudinal NHI registration data for healthcare
institutions and physicians.
Establishment of a PMV patient cohort
We used SAS software version 9.1.3 (SAS Institute Inc.,
Cary, NC) to extract, organize, and link each patient’sd a t a
on NHI registration and hospital care, and death certifi-
cate data. As the BNHI counts the lengths of short periods
of discontinuation of MV care that was 4-day long or
shorter when determining PMV status, we combined inpa-
tient data for two admissions requiring MV for analysis if
the readmission was within 4 days after the discharge of
the previous admission. We defined such two admissions
as a same episode of hospital stay for later analysis.
Although the BNHI has data on the exact dates of days
with MV, the database we acquired only includes informa-
tion on the amount of MV services for each medical order
that was measured in days. Thus, we had to determine
PMV status by counting the total number of days with
MV in a hospital stay. For an episode of hospital stay that
included two or more admissions requiring MV, we
counted the number of days of short periods between two
admissions when calculating the total number of days with
MV. A hospital stay that had 21 or more days with MV
was defined as one with a PMV incidence. To determine
the time of a PMV onset, we assumed that MV services
were offered right in the middle of a hospital stay with 21
or more days of MV to determine the 21
st day of MV use,
which was the time of the PMV onset.
Taking into account the requirements of the NHI care
program for PMV patients, we added two more criteria
for selecting study patients: (1) use of invasive ventila-
tors or negative pressure ventilators at the initiating
stage of care, and (2) > = 17 years of age on the 21
st day
of MV. We also confined the patient cohort to those
becoming under PMV in or after 1998, when use of MV
started to receive much attention. Finally, we decided to
include in our project database only data for patients
whose 1-year survival could be observed. Note that
some patients used mechanical machines on and off,
and had multiple episodes of PMV. Our study focuses
on episodes that had at least a period of time of 365
days from all prior hospital stays with MV. This is based
on an idea that findings from investigating outcomes
among “new” patients with PMV can provide more
reference information to physicians and policy makers,
compared with results from examining future outcomes
among patients who have been using MV services con-
tinuously or intermittently for months or even years.
We finally identified 50,481 new patients who became
under PMV in 1998-2006.
Validation of data on PMV status and the time of PMV
incidence
Because we counted the number of days of short periods
between two admissions when calculating the total
number of days with MV, some patients in our PMV
patient cohort might actually order fewer than 21 days
of MV services. To examine whether this might have a
significant influence on accuracy of identification of
PMV status, we investigated the proportion of patients
in the study cohort who ordered MV services for fewer
than 21 days. The proportion was 0.5%, suggesting that
bias due to wrong identification of PMV status was
minor. Furthermore, we calculated the ratio of “the total
number of days with medical orders for MV services” to
“the counted number of days with MV” (including short
periods between two admissions requiring MV) for each
patient. The average ratio of the 50,481 patients was
0.99. Only 2% of the patients had a ratio smaller than
0.8, while 87% had a ratio equal to 1. These results indi-
cate that this project has minor inaccuracy in identifying
PMV patients and determining the time of PMV onset.
Study participants
We selected new PMV patients in 1998-2003 to assure a
complete 4-year follow-up observation for each patient
surviving the end of 2007. The inclusion criteria for
these patients were: (1) continuous use of invasive venti-
lators, negative pressure ventilators, and/or positive
pressure ventilators for at least 21 days, (2) use of inva-
sive ventilators or negative pressure ventilators at the
initiating stage of care; (3) > = 17 years of age on the
21st day of MV; (4) the date of the 21
st day of MV fall-
ing in 1998-2003; and (5) no use of invasive ventilators,
negative pressure ventilators, and positive pressure ven-
tilators for at least one year before the first day of this
PMV event. We excluded patients with missing data for
gender in descriptive analysis, and further excluded
those with missing data for other explanatory variables
in modelling survival prediction. The proportion of
patients with missing data in the NHI database was very
small. Exclusion of these patients from the study sample
would not result in substantial bias.
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For each patient passing away before the end of 2007,
we calculated post-PMV survival time as the period
between the day of PMV incidence and the death date.
For each patient who was alive at the end of 2007, we
calculated post-PMV survival time that was censored at
the end of 2007, and created a marker variable to
denote right-censored data. Outcome variables for mod-
elling survival prediction included binary variables show-
ing 3-month, 6-month, 1-year, 2-year, 3-year and 4-year
survival status after the PMV onset, with a value of
1 indicating successful survival and a value of 0 denot-
ing failure. Data on factors associated with survival were
from the NHI database. We counted the total number
of days alive free of hospital stays with MV in the 4
years following a PMV incidence by subtracting the sum
of the lengths of all hospital stays requiring MV in the 4
years following the PMV onset from the length of survi-
val time in the immediate 4-year period after PMV.
Modelling survival prediction
We estimated 3-month, 6-month, 1-year, and 2-year survi-
val models to determine factors associated with survival
and construct prediction functions for survival among
PMV patients. For each survival model (3-month,
6-month, 1-year, or 2-year), we established a set of hospi-
tal and patient factors that were potentially influencing on
survival. Other factors included diseases being diagnosed
during the index hospital stay and during hospital stays in
the immediate 1-year period before PMV.
Variables of hospital characteristics at the PMV onset
included a set of binary variables indicating a hospital’s
accreditation level and region. The accreditation level of a
hospital in Taiwan reflects the hospital’s size and clinical
capabilities [9]. The region of a hospital in Taiwan might
capture effects on hospital behaviours or outcomes of the
managerial pattern of a regional NHI office, as there are 6
regional NHI branch offices. We also included a continu-
ous variable showing the year of PMV incidence. This
variable was a proxy for capturing the effect of generous
NHI coverage on PMV care on the trend in expanding
MV care use to prolong a PMV patient’s life over time
after the new care policy.
Patient characteristics included a patient’sg e n d e ra n d
age, which are generally associated with disease prognosis.
Also included was a set of binary variables indicating the
urbanization level of a patient’s NHI registration location
that was measured according to population density and
the local industrial pattern [10]. To estimate the effect of a
patient’s socioeconomic status, we included a set of binary
variables showing the salary tertile.
Variables of diseases included a set of binary variables
indicating conditions reported at the PMV onset, and a
set of count variables showing the numbers of hospital
admissions for treating various conditions in the immedi-
a t e1 - y e a rp e r i o db e f o r eP M V .T oc l a s s i f yd i s e a s e s ,w e
first used the Clinical Classifications Software developed
by the U.S. Agency for Healthcare Research and Quality
to categorize all diseases [11], and further reduced the
number of disease classes down to 43 after discussion
with physicians in related fields (see Additional file 1).
While NHI claims data for reimbursement purposes do
not provide very detailed information on disease categor-
ization for each admission, the general quality of NHI
data on disease diagnosis is acceptable [9]. After discus-
sion with physicians in related fields, we believed that
inpatient NHI data on disease diagnosis were adequate
for this study, which looks into major and broad disease
categories. We excluded variables for “respiratory failure”
from the two sets of variables of diseases, because most
physicians would include this diagnosis for PMV patients.
Statistical analysis
We used Stata software version 9 (StataCorp, College Sta-
tion, TX) for both descriptive statistics and multivariable
regression analysis. Our descriptive analysis investigated
survival up to 4 years, and examined the total length of
time free of hospital stays with MV in the immediate
4-year period after PMV. Binary variables indicating suc-
cessful survival were reported as percentage. The number
of days alive free of hospital stays with MV was shown by
selected percentiles (including minimum, median, maxi-
mum, and some others), mean and standard deviation.
Our estimation of prediction models focused on survival
of 2 years or less, as a primary purpose of the prediction
was to identify patients who were expected to die in a near
future. Prediction of the likelihood of surviving a specific
period of time can potentially yield information for facili-
tating communication with patients approaching the end
of life and their family. We adopted logistic regression to
identify factors associated with 3-month, 6-month, 1-year,
and 2-year survival, and generate coefficient estimates for
predicting a specific patient’s probabilities of surviving dif-
ferent lengths of time. Compared to other contemporary
methods of survival analysis, logistic regression is a very
understandable method for generating predictions of sur-
vival likelihood and conducting subsequent comparison of
predicted outcomes with actual outcomes to assess the
quality of predictions.
Among explanatory variables for survival prediction,
binary variables of hospital and patient characteristics
were reported as percentage. Both the binary variables and
the count variables indicating morbid conditions were
reported as percentage on the basis of the proportion of
patients with a non-zero value. To examine collinearity
between explanatory variables, we calculated the variance
inflation factor (VIF) for each variable, and the mean value
of all VIFs. Results of the collinearity diagnostics indicate
Lu et al. BMC Health Services Research 2012, 12:100
http://www.biomedcentral.com/1472-6963/12/100
Page 4 of 13that inclusion of these variables would not result in dama-
ging collinearity for multivariable regression analysis.
For comparison purposes, we used the probit regression
method to estimate survival models. To investigate
whether morbid conditions before PMV significantly influ-
enced post-PMV survival, we also estimated survival mod-
els that excluded from explanatory factors the count
variables showing the numbers of hospital admissions for
treating various conditions in the immediate 1-year period
before PMV. Additionally, we used a stepwise approach
for selecting explanatory variables of diseases. We decided
not to use the stepwise approach to select hospital and
patient characteristics in model estimation, and included
all of them. Because each hospital or patient feature was
represented by a set of binary variables, it was thus not
appropriate to use the stepwise approach for selecting
variables among all these variables. We presented the
results of survival models by reporting adjusted odds ratios
(ORs) of explanatory variables and their 95% confidence
intervals, and using a significant level of 5%. Data of 1998-
2002 were used to estimate prediction functions; the 2003
data were employed to investigate model performance.
The cutoff value of predicted survival probability for
classifying patients
We selected 10% as the cutoff value of predicted probabil-
ity to identify patients with low survival likelihood and
classify patients after prediction. With this level of cutoff
value, patients with a predicted probability of survival <
10% would be classified as a group that would die before
the end of observation period, and those with a predicted
probability of survival > = 10% would be classified as a
group that would survive the whole observation period.
There is no universal standard for choosing a cutoff value
for prediction modelling; one criterion for judging appro-
priateness of the level of cutoff value is weighing benefits
and harms due to decisions based on wrong predicted out-
comes [12]. After discussion with some physicians in
intensive care, we decided that 10% was an appropriately
low survival probability for identifying patients who would
be expected to pass away in a near future, to assure a
small chance of wrongly categorizing a patient into a
group with predicted death.
Using data for PMV patients of 2003, we compared
predicted outcomes with actual outcomes, and further
calculated four measures for reflecting the quality of pre-
dictions in different perspectives. The four measures and
their formulae are below:
(1) sensitivity = (the number of patients with a pre-
dicted probability of survival > = 10%)/(the number of
patients who actually survive the whole observation
period);
(2) specificity = (the number of patients with a pre-
dicted probability of survival < 10%)/(the number of
patients who actually died before the end of observation
period);
(3) positive predicted value (PPV) = (the number of
patients who actually survive the whole observation per-
iod)/(the number of patients with a predicted probability
of survival > = 10%);
(4) negative predicted value (NPV) = (the number of
patients who actually died before the end of observation
period)/(the number of patients with a predicted prob-
ability of survival < 10%).
Sensitivity measured the proportion of patients with a
correct predicted outcome among those actually surviving
the whole observation period. Specificity measured the
proportion of patients with a correct predicted outcome
among those actually passing away during the observation
period. PPV indicated the proportion of patients who did
survive the whole observation period among those who
were expected to survive. NPV showed the proportion of
patients who did die during the observation period among
those who were expected to die. As shown by these for-
mulae, the directions of changes in sensitivity and in speci-
ficity are reversed, and the directions of changes in PPV
and in NPV are reversed.
We emphasized NPV when assessing the quality of pre-
dictions, because we aimed to reduce the number of
patients being wrongly classified into a group with antici-
pated death in a near future (called “false negative cases”
in statistics). During communication concerning future
healthcare for a PMV patient, data on NPV can provide
the patient and the family reference information in regard
to whether a patient with an anticipated death in a near
future according to PMV patients’ prognosis in the past
would really pass away soon. Using this standard of asses-
sing the quality of predictions, we inevitably had a low
accuracy level for detecting death cases among those who
actually died.
We also calculated one more performance measure:
the c-statistic. This measure is also termed as AUC,
w h i c hi n d i c a t e st h ea r e au n d e rt h er e c e i v e ro p e r a t i n g
characteristic curve. It assesses the extent to which pre-
dicted outcomes discriminate between subjects with dif-
ferent actual outcomes. In addition to using the log-
likelihood ratio test to examine model significance, we
used the c-statistic to evaluate the overall adequacy of a
prediction model.
Results
Study participants and their survival rates
There were 25,482 new patients during 1998-2003. In esti-
mation of prediction models and following post-estimation
calculations, we further excluded 732 patients with miss-
ing data for potential predictors in model estimation.
Modelling survival prediction used 19,127 new patients in
1998-2002, and validation of model performance used
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process of study subjects are in Figure 1.
Among new PMV patients in 1998-2003, the 3-month
survival rate was 51.4%, the 1-year survival rate was
31.9%, and only 17.5% of these patients could survive 4
years (Table 1). Compared to new patients of years in
the late 1990s, new patients in years after 2000 generally
had higher survival rates in the immediate 3-month per-
iod after PMV, but their 3-year and 4-year survival rates
appeared poorer (Table 1).
Factors associated with survival
We reported results from the logistic models with the
whole set of explanatory variables. Models with alterna-
tive specifications had results very similar to this set of
models, but generally had lower values for the c-statistic.
Log-likelihood ratio test for examining model signifi-
cance also tended to favour the models reported here.
These survival-prediction models identified many factors
significantly associated with post-PMV survival (Table 2
and Additional file 2; all ORs were adjusted for all other
covariates). Each survival model had a c-statistic > = 0.7,
suggesting that the model performance had an acceptable
level (see Additional file 3).
Five disease types are particularly noteworthy: neo-
plasm, acute and unspecific renal failure, shock, chronic
renal failure and septicemia (Table 2). Each had a sub-
stantial prevalence rate, and was associated with a low
OR that indicated significantly lower survival (OR < 0.65,
p < 0.01). Non-alcoholic liver disease was also a signifi-
cant problem, with a substantial prevalence rate and a
significant associated with lower 3-month and 6-month
survival (OR < 0.7, p < 0.01). Heart failure and diabetes
mellitus were two more salient health conditions asso-
ciated with lower survival (OR < 0.8, p < 0.01). (See Addi-
tional file 2 for OR figures for all other diseases.)
Several diseases that caused hospital care use within
one year before PMV were also associated with post-
PMV survival. Four disease categories especially call for
further research: neoplasm, other diseases of blood and
blood-forming organs (the ICD-9 code = 289), chronic
renal failure, and non-alcoholic liver disease (Table 2).
The numbers of admissions for treating these diseases in
the immediate 1-year period before PMV were signifi-
cantly associated with lower post-PMV survival.
An older age was significantly associated with worse
survival, and males had poorer survival (Table 2). With
all other factors being controlled for, new patients of a
l a t e ry e a rt e n d e dt oh a v eh i g h e rs u r v i v a l ,s u g g e s t i n ga n
increasing time trend in adjusted survival (Additional file
2). Patients’ demographics and socioeconomic condi-
tions, as well as hospital characteristics at the PMV
onset, were related to survival (Additional file 2). In
general, patients in the middle tertile of NHI salary class
seemed to have poorer survival than those in the other
two tertiles. Patients in the very south region in Taiwan
(the Kao-Ping region) appeared to have poorer survival,
and those staying in a medical centre at the PMV onset
tended to have higher survival.
Performance of survival models
With 10% being the cutoff value for predicated probability,
78 (1.4%), 238, (4.2%), 604 (10.7%) and 1,193 (21.2%)
patients among those becoming under PMV in 2003 were
chosen as patients with anticipated death (negative cases)
within 3 months, 6 months, 1 year, and 2 years after PMV,
respectively (Table 3). Although only a low to moderate
proportion of patients who actually passed away within
the observation period were identified by the prediction,
the majority of selected patients had corrected predictions,
as shown by the NPVs. For 3-month, 6-month, 1-year and
2-year prediction models, the NPVs were, respectively,
87.2%, 87.0%, 89.9%, and 92.1% (Table 3).
One more measure reflecting the quality of predictions
is the proportion of subjects with corrected predictions.
With the 10% cutoff value, 54.1%, 45.1%, 41.0%, and 41.5%
among all patients of year 2003 had correct predictions in
the 3-month, 6-month, 1-year and 2-year prediction mod-
els (Additional file 4). The low rate of correct classification
was caused by our conservative threshold for identifying
patients with anticipated death. With 50% being the cutoff
value, we would have a much higher rate of correct classi-
fication. Nevertheless, sensitivity suffers in this case (see
Additional file 4). At this threshold, 65.6%, 66.8%, 71.4%,
and 78.6% among all patients of year 2003 had correct pre-
dictions in the 3-month, 6-month, 1-year and 2-year pre-
diction models (Additional file 4).
The number of days alive free of hospital stays requiring
MV services following a PMV incidence
Inpatient NHI data for new PMV patients of year 2003
who had a predicted survival probability < 10% suggest
that they would spend most of their rest of life in hospital
stays requiring MV services (Table 4). During the 4-year
follow-up time, 75% among patients with anticipated
death within 6 months after PMV (the 6-month survival
rate < 10%) had 15 or fewer days free of hospital stays
requiring MV, and 75% among patients with anticipated
death within 2 years after PMV (the 2-year survival rate <
10%) had 25 or fewer days free of hospital stays requiring
MV. In contrast, for the whole sample of 2003 PMV
patients, the length of time free of ventilation-related
inpatient services during the 4-year follow-up time was
significantly longer; at least 25% of the patients could
have 175 or more days free of hospital stays requiring
MV. In the 4-year follow-up period, the mean number of
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with a predicted 6-month survival rate < 10%, and 111.3
in those with a predicted 2-year survival rate < 10%. In
the whole sample of patients in 2003, the mean number
of days was 256.9.
Discussion
Among these PMV patients, the 3-month survival rate
was 51.4%, the 1-year survival rate was 31.9%, and only
17.5% of them could survive 4 years. Common health
conditions with significant associations with poor
A sub-sample obtained after simple random sampling with a 
fraction of 1/(3.4) to reduce the sample size to 10% of the 
whole population (the upper limit of sample size for using 
National Health Insurance data) 
(n=2,619,534; 10% of all enrollees ever alive in the 12 years) 
New patients with prolonged mechanical ventilation in 1998-2006
(to allow at least 1-year observation after the event and at least 
1-year observation before the event for each patient, and to 
focus on patients in or after 1998, when use of mechanical 
ventilation started to receive much attention) 
(n=50,481) 
Inclusion criteria:
(1) Continuous use of 
invasive ventilators, 
negative pressure 
ventilators, and/or 
positive pressure 
ventilators for at least 21 
days 
(2) Use of invasive 
ventilators or negative 
pressure ventilators at 
the initiating stage of 
care 
(3) >=17 years of age on 
the 21
st day of 
mechanical ventilation 
(4) The date of the 21
st day 
of mechanical 
ventilation falling in 
1998-2006 
(5) No use of invasive 
ventilators, negative 
pressure ventilators, and 
positive pressure 
ventilators for at least 
one year before the first 
day of this event of 
prolonged mechanical 
ventilation
New patients with prolonged mechanical ventilation in 1998-
2003 for descriptive analysis 
(to allow at least 4-year observation after the event for each case)
(n=25,482) 
New patients in 1998-2002 for 
estimation of prediction models 
(n=19,127) 
New patients in 2003 for model 
performance investigation 
(n=5,623) 
Exclusion criterion: 
With missing data for other 
explanatory variables in 
model estimation (n=603 
(3.1%) for 1998-2002, 
n=129 (2.2%) for 2003) 
Exclusion criteria: 
(1) The date of the 21
st day 
outside the period from 
1998-2003 (n=24,963) 
(2) Missing data for gender 
(n=36)
Patients who ever used invasive or non-invasive respiratory 
care in the National Health Insurance (NHI) in 1996-2007 
(n=8,906,406; 34% of all enrolees ever alive in the 12 years) 
Figure 1 Flow diagram of the selection process of study subjects.
Lu et al. BMC Health Services Research 2012, 12:100
http://www.biomedcentral.com/1472-6963/12/100
Page 7 of 13Table 1 Post-PMV survival rates, by year of PMV onset (%)
Year
Time of follow-up
1998 1999 2000 2001 2002 2003 1998-2003
n = 2,537 n = 3,699 n = 3,770 n = 4,546 n = 5,178 n = 5,752 n = 25,482
3 months 49.7 50.5 49.1 50.8 52.2 54.0 51.4
6 months 40.2 40.3 39.5 39.6 41.5 43.1 40.9
1 year 32.2 31.3 31.0 30.4 32.2 33.7 31.9
2 years 25.8 24.3 24.0 23.3 24.3 25.1 24.4
3 years 23.1 20.3 20.5 20.0 19.5 20.2 20.4
4 years 21.2 17.8 18.3 16.6 16.4 16.7 17.5
PMV prolonged mechanical ventilation
Table 2 Adjusted odds ratios for selected predictors of post-PMV survival and sample characteristics*
3-month
survival
6-month
survival
1-year survival 2-year survival % patients
with the
feature
Predictor
‡ OR
† 95% CI OR
† 95% CI OR
† 95% CI OR
† 95% CI
Diagnoses at PMV onset (excluding respiratory failure)
Neoplasms 0.30** 0.27-0.34 0.31** 0.27-0.36 0.30** 0.26-0.35 0.31** 0.26-0.38 13.6
Acute and unspecified renal failure 0.39** 0.34-0.45 0.40** 0.35-0.47 0.48** 0.41-0.57 0.56** 0.47-0.67 7.7
Shock 0.42** 0.38-0.47 0.47** 0.42-0.53 0.55** 0.48-0.62 0.63** 0.55-0.73 11.2
Chronic renal failure 0.44** 0.37-0.51 0.43** 0.36-0.52 0.41** 0.33-0.50 0.43** 0.34-0.54 6.3
Septicemia 0.52** 0.48-0.57 0.56** 0.51-0.61 0.60** 0.54-0.66 0.63** 0.56-0.70 20.3
Non-alcoholic liver disease 0.60** 0.51-0.71 0.67** 0.56-0.81 0.72** 0.60-0.88 0.84 0.69-1.03 4.5
Heart failure 0.77** 0.68-0.87 0.76** 0.67-0.86 0.79** 0.69-0.91 0.77** 0.66-0.90 9.1
Diabetes mellitus 0.78** 0.71-0.85 0.77** 0.70-0.85 0.72** 0.65-0.79 0.73** 0.65-0.81 21.0
Disease history (number of admissions for the disease in the previous year; excluding respiratory failure)
Other diseases of the blood and blood-forming organs 0.85** 0.80-0.91 0.83** 0.77-0.90 0.78** 0.72-0.86 0.80** 0.73-0.89 12.6
Non-alcoholic liver disease 0.86** 0.80-0.93 0.86** 0.79-0.94 0.89* 0.81-0.98 0.92 0.83-1.01 6.8
Neoplasms 0.91** 0.88-0.95 0.89** 0.84-0.93 0.88** 0.83-0.93 0.89** 0.84-0.94 14.4
Chronic renal failure 0.91** 0.85-0.97 0.88** 0.81-0.95 0.83** 0.75-0.92 0.78** 0.69-0.89 6.9
Gender (ref: female)
Male 0.89** 0.83-0.95 0.84** 0.78-0.90 0.79** 0.74-0.85 0.78** 0.72-0.84 60.1
Age group (ref: 17-34)
35-44 0.67** 0.51-0.87 0.64** 0.49-0.83 0.61** 0.47-0.79 0.65** 0.51-0.84 3.3
45-54 0.67** 0.52-0.85 0.60** 0.48-0.76 0.54** 0.43-0.69 0.55** 0.44-0.70 6.2
55-64 0.62** 0.49-0.78 0.52** 0.41-0.65 0.43** 0.35-0.54 0.39** 0.32-0.49 11.2
65-74 0.44** 0.36-0.55 0.36** 0.29-0.44 0.28** 0.23-0.35 0.25** 0.20-0.31 26.7
75-84 0.36** 0.29-0.44 0.27** 0.21-0.33 0.19** 0.15-0.23 0.16** 0.13-0.20 35.2
≥ 85 0.29** 0.23-0.36 0.21** 0.17-0.26 0.15** 0.12-0.19 0.11** 0.09-0.14 14.7
Number of patients 19,127* 19,127* 19,127* 19,127* 25,482*
Model significance (results from log-likelihood ratio tests) c
2(103) =
3,099.81**
c
2(103) =
3,032.36**
c
2(103) =
2,939.46**
c
2(103) =
2,652.06**
PMV prolonged MV
OR odds-ratio.
CI confidence interval.
* p < 0.05; ** p < 0.01.
* The sample for survival model estimation includes patients from 1998 to 2002, and the sample for describing patient characteristics includes patients from
1998 to 2003.
† The OR was adjusted for all other covariates. Covariates in the model included hospital characteristics at the episode onset (hospital type, hospital location),
and individual demographics (gender, age, NHI registration location), year of incidence, socioeconomic conditions (salary class in NHI registration), diseases
reported at the episode onset (except respiratory failure), and diseases causing hospital care use within the year before the episode (except respiratory failure).
‡ The table only shows OR figures for selected explanatory variables; OR figures for all explanatory variables are shown in a supplementary file (Additional file 2).
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Page 8 of 13survival included neoplasm, acute and unspecific renal
failure, chronic renal failure, non-alcoholic liver disease,
shock and septicaemia. During a 4-year follow-up period
for patients of year 2003, 75% of those with a predicted
6-month survival rate < 10% and 75% of those with a
predicted 2-year survival rate < 10% had, respectively, at
most 15 and 25 days free of hospital stays requiring
MV. In contrast, at least 25% of all patients could have
175 or more days free of hospital stays requiring MV.
Strengths and limitations
T h em a j o rs t r e n g t h so ft h i ss t u d yi n c l u d eu s eo fa
large and nationally representative sample of PMV
patients, and the long follow-up time. The rich content
and reliable quality of NHI data and death certificate
data add additional strengths to this study. Our inves-
tigation of “the total length of time free of hospital
stays requiring MV in following years after a PMV
onset” increases knowledge on post-PMV prognosis, as
past studies mainly examined survival rates and in-hos-
pital weaning rates. This study also identifies several
common health conditions with significant associations
with poor survival. Empirical findings from this study
can certainly improve reference data for facilitating
communication among participants in care planning
for PMV patients.
Table 3 Performance measures of survival models, with the cutoff value for predicted probability = 10%,* for the
2003 sample
Measure Sensitivity
† Specificity
† PPV
† NPV
†
n % (se) n % (se) n % (se) n % (se)
3-month survival 2974/2984 99.7 (0.1) 68/2639 2.6 (0.3) 2974/5545 53.6 (0.7) 68/78 87.2 (3.8)
6-month survival 2329/2360 98.7 (0.2) 207/3263 6.3 (0.4) 2329/5385 43.3 (0.7) 207/238 87.0 (2.2)
1-year survival 1762/1823 96.7 (0.4) 543/3800 14.3 (0.6) 1762/5019 35.1 (0.7) 543/604 89.9 (1.2)
2-year survival 1235/1329 92.9 (0.7) 1099/4294 25.6 (0.7) 1235/4430 27.9 (0.7) 1099/1193 92.1 (0.8)
PPV: positive predictive value
NPV: negative predictive value
se: standard error
* As 10% was chosen as the cutoff value for predicted probability, patients with a predicted probability of survival < 10% were classified as a group that would
die before the end of observation period, and those with a predicted probability of survival > = 10% were classified as a group that would survive the whole
observation period. By comparison of predicted outcomes with actual outcomes, we further calculated the four measures for reflecting the quality of predictions
in different perspectives.
† The formulae for these measures are below:
sensitivity = (the number of patients with a predicted probability of survival > = 10%)/(the number of patients who actually survive the whole observation
period);
specificity = (the number of patients with a predicted probability of survival < 10%)/(the number of patients who actually died before the end of observation
period);
PPV = (the number of patients who actually survive the whole observation period)/(the number of patients with a predicted probability of survival > = 10%);
NPV = (the number of patients who actually died before the end of observation period)/(the number of patients with a predicted probability of survival < 10%).
Table 4 Number of days free of hospital care related to MV in the 4-year after PMV*
min. 25% Median 75% 80% 85% 90% 95% max. mean SD
Cases with a predicted probability for 3-month survival < 10%
†
(n = 78, 1.4% of the 2003 sample; 87.2% of them were actually deceased within 3 months after PMV.)
Number of days free of hospital stays requiring MV 0 0 3 15 19 27 38 279 1,331 39.8 165.2
Cases with a predicted probability for 6-month survival < 10%
†
(n = 238, 4.2% of the 2003 sample; 87.0% of them were actually deceased within 6 months after PMV.)
Number of days free of hospital stays requiring MV 0 0 1 13 17 34 111 385 1,459 66.0 242.3
Cases with a predicted probability for 1-year survival < 10%
†
(n = 604, 10.7% of the 2003 sample; 89.9% of them were actually deceased within 1 year after PMV.)
Number of days free of hospital stays requiring MV 0 0 1 17 31 68 174 570 1,460 90.2 285.8
Cases with a predicted probability for 2-year survival < 10%
†
(n = 1,193, 21.2% of the 2003 sample; 92.1% of them were actually deceased within 2 years after PMV.)
Number of days free of hospital stays requiring MV 0 0 2 24 43 95 280 1,018 1,460 111.3 318.1
The whole sample of year 2003 (n = 5,623)
Number of days free of hospital stays requiring MV 0 0 6 175 382 834 1,383 1,447 1,460 256.9 482.2
PMV prolonged MV
SD standard deviation
* For this description, we used data for the 2003 patient sample, which was the external validation sample for the survival prediction models.
† The predicted outcome for these patients was death.
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Page 9 of 13The major limitation for this study is lack of more
detailed physiological and biochemical data. Certain bio-
chemical markers and conditions of organ failure are
expected to greatly improve the quality of survival pre-
dictions. However, the Taiwan government has not
incorporated a system of storing such data into the NHI
database yet. With insufficient predictors, prediction
models in this study can only have fair performance. As
t h es u r v i v a lp r e d i c t i o nm o d e l sd on o th a v eav e r ys t r o n g
capability of discriminating between actual survival and
death cases, and we have to be conservative in selecting a
cutoff value for predicted outcomes, this prediction sys-
tem can only identify a small proportion of patients who
would actually decease soon. This prediction system also
lacks capability of providing comprehensive information
on patients’ cognitive ability, pain and functional status
after a PMV onset.
PMV incidence rates
Taiwanese experience indicates that the incidence rate of
PMV is high under a national health insurance program
with generous coverage of inpatient MV services. More
than 0.1% of all Taiwanese receive PMV annually. This
rate appears slightly higher than that for the United States,
where around 300,000 patients use this type of healthcare
in ICUs, long-term acute care facilities or specialised
weaning units per year [13]. In contrast, the rate for a U.K.
region with no dedicated weaning unit may be much
lower, as a research in this region reports that there were
around 70 cases with PMV annually in this region of
900,000 residents in 2002-2006 [14].
Post-PMV prognosis
We adopted survival, particularly long-term survival, as
the main outcome for our investigation, instead of another
important performance indicator for MV services: wean-
ing. While the literature presents different definitions for
successful weaning [1,15-19], follow-up time for weaning
is usually a period of a few days, and an experience of suc-
cessful weaning is not necessarily followed by long-term
liberation from MV or survival. We looked into long-term
survival rather than in-hospital survival, the outcome
measure in most past studies [1,18,20-29]. To provide
information on whether a patient can have anticipant
long-term liberation from MV, we used “the length of sub-
sequent time free of hospital stays requiring MV after a
PMV onset” as an indicator.
Our study found 3-month and 1-year survival rates
(51.4% and 31.9%, respectively) similar to those observed
in a U.S. university-based tertiary-care hospital [30], sug-
gesting that patients with PMV have poor survival even in
societies with high levels of providing MV care. Persistent
poor functional status after a PMV incidence was observed
among most patients in a U.S. study that was based on
5 intensive care units [13]. Similarly, our findings suggest
that many Taiwanese patients would have poor ability to
perform daily activities for most of their life after a PMV
incidence. Research has indicated that almost 75% of Tai-
wanese patients under PMV in hospitals showed suffering
from pain or discomfort, and over 60% had poor cognition
[31]. Furthermore, even among patients with fair to good
cognition during hospital stays with PMV, over 80% were
confined to bed, and unable to have any self-care or usual
activities [31]. A condition of staying in a hospital for
using MV care appears to be significantly associated with
poor ability for performing daily life activities. As our
study found that many PMV patients in Taiwan tend to
spend most of the rest of life staying in hospitals for using
MV services, it suggests that persistent low ability for per-
forming daily activities is expected after a PMV incidence.
Care planning for PMV patients
Over-optimistic expectations for outcomes of PMV may
induce overuse of MV care [32]. While MV services may
prolong a patient’s life, they do not necessarily improve
welfare for the patient or the patient’s family. Insufficient
communication between physicians and patients or their
surrogates is a problem potentially causing inappropriate
decisions on using long-term MV care [32]. Over recent
years, the “paternalistic model” in the health care system
has gradually been replaced by a shared decision-making
model [33]. How to clearly present evidence on anticipant
poor outcomes to facilitate communication for reducing
inappropriate use of MV services is a challenge to both
physicians and policy makers. For patients with substantial
likelihood of being weaned from MV, the healthcare sys-
tem has to provide necessary care and an ideal care path
to facilitate the process of weaning. On the other hand, it
is also important that the healthcare system has to provide
a mechanism to help those wishing to terminate PMV
services after endeavour for survival.
In 2000, the Taiwan government revised the law to
allow withholding of life-sustaining treatment under the
condition that this is the preference of a patient
approaching the end of life or the patient’sf a m i l y .
Nevertheless, this revision of law did not make withdra-
wal of life-sustaining treatment a lawful act. In 2002, the
government revised the law again to allow withdrawal of
life-sustaining treatment for a patient approaching the
end of life who has written a document indicating the
preference. Physicians’ dilemma in responding to the
preference of PMV patients or their families for with-
drawing life-sustaining treatment remained for almost a
decade after this law revision. Many PMV patients did
not write any documents showing their preference for
withdrawing MV services before they became perma-
nently unconscious. In such a case, physicians could not
terminate a patient’s MV, even when they knew that
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Page 10 of 13this was the patient’s wish or what the patients’ family
hoped.
In January of 2011, the government further revised the
law to conditionally allow terminal withdrawal of MV for
permanently unconscious PMV patients approaching the
end of life who previously expressed preference for ending
life-sustaining treatment but have left no written docu-
ments indicating the preference. For such a patient, the
family can make a request for terminating PMV services if
each of the living spouse, living adult children, living adult
grandchildren, and living parents agrees upon the request.
The request can only be approved after an ethics commit-
tee organized by the patient’s hospital evaluates and agrees
upon the request. By the law, at least one third of mem-
b e r si ns u c hac o m m i t t e eh a v et ob ee x p e r t si ne t h i c so r
law, or persons from the public.
Once a family makes such a request, physicians have to
communicate with the family, and help the family to sub-
mit the request to an ethics committee if appropriate. In
some cases, patients’ families may seek help from physi-
cians for assessing whether it is appropriate to continue
PMV care. The medical society of Taiwan is currently
searching for good guidelines in order to well implement
such intervention. One of many essential tasks for con-
structing guidelines is to generate good reference informa-
tion on disease prognosis that can facilitate assessment of
requests to terminate PMV services, communication with
families making the requests, and preparation of applica-
tion materials for the ethical reviews of the requests.
When confronting requests to help with application for
termination of PMV services, physicians can first use their
patients’ data from medical charts and NHI records, and
refer to these results shown by NHI data for a national
representative sample of PMV patients, to assess the
appropriateness of the application. Our findings show that
patients who receive PMV and have low 3-month,
6-month, 1-year or 2-year survival likelihood by prediction
are highly likely to have very poor outcomes in following
years. For appropriate cases, information generated by this
study can also serve as reference materials to ethics
committees.
Information system for improving PMV care
To identify patients highly likely to have poor future out-
comes is a task of high priority for improving care patterns
for PMV patients [34]. This study is an effort to use
national health insurance claims and registration data, and
death certificate data to construct a prediction model of
long-term outcomes of PMV. It aims to advance under-
standing in this regard, and to generate an information
system that can promote reasonable decisions on whether
to continue PMV care or to choose another care pattern.
In Taiwan, each NHI enrolee has an electronic identifi-
cation card. A healthcare institute can retrieve a patient’s
background information with the patient’s card and per-
mission from the government. Thus, it is feasible to
establish the information system that we propose at a
low cost. The government can use recently updated
population data to generate new parameters for predic-
tion every year to help physicians have better communi-
cation with other participants involved in clinical
decisions in regard to PMV care. Although insurance
claims data do not provide detailed information on
physiologic and biochemical variables, the discrimination
model established by this study has acceptable perfor-
mance. With additional effort to input important physio-
logic and biochemical variables into the NHI database for
severely ill patients, we may further construct a discrimi-
nation model with better performance. Countries with
administrative data of public health services may also
take advantage of such data to construct an information
system for improving clinical communication and deci-
sion-making processes with respect to PMV care.
It is certain that even such large amounts of quantitative
reference data alone are unable to provide sufficient infor-
mation for making decisions on healthcare for PMV
patients. Nevertheless, better reference data may help
patients, their families, physicians and participants in
reviewing requests to terminate PMV care make better
decisions that advance quality of life for individual patients
at the end of life. The endeavour to construct more data
on disease prognosis among PMV patients conforms to
widely-accepted moral principles for formulating guide-
lines for clinic and public health practice in a publicly
funded healthcare system: (1) respect for autonomy, (2)
non-maleficence, (3) beneficence, and (4) justice [35].
Such effort is expected to enhance autonomy in choice of
healthcare, and advance more rational discussion on PMV
care use.
The final point to be mentioned is that we need to
quickly establish more and clearer guidelines on providing
MV services to patients with the following diseases: neo-
plasm, acute and unspecific renal failure, chronic renal
failure, and non-alcoholic liver disease. It calls for more
research on appropriateness of providing MV to patients
at different prognosis stages of these diseases. With more
reference information generated from data of large repre-
sentative samples, we will have better opportunities to
construct clinical guidelines with high persuasion and
practical value to the public.
Conclusions
Neoplasm, acute and unspecific renal failure, shock,
chronic renal failure, septicemia, and non-alcoholic liver
disease are significantly associated with poor survival
among PMV patients. Patients with anticipated death in
a near future tend to spend most of the rest of their life
staying in hospital using MV services. This calls for
Lu et al. BMC Health Services Research 2012, 12:100
http://www.biomedcentral.com/1472-6963/12/100
Page 11 of 13further research into assessing PMV care need among
patients at different prognosis stages of diseases listed
above.
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